drugset / Trial / NCT07087314

A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence

NCT07087314 ↗

Phase 2 Recruiting 30 enrolled Mao Jianhua
NaSingle-groupOpen-labelTreatment

Summary

This is an open - label study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of SG301 Subcutaneous injection in children with frequently relapsing or steroid - dependent nephrotic syndrome.

Timeline

Start
2025-08-25
Primary completion
2028-07-09
Completion
2029-07-09

Drugs

EvaluationDrugModalityDoseRoute
Subject SG301 Monoclonal antibody 10 mg/kg —

Indications